Enzyme replacement therapy improves cardiac features and severity of Fabry disease

Molecular Genetics and Metabolism

Volumn 107, Issue 1-2, 2012, Pages 197-202

  Motwani, Manish ^a   Banypersad, Sanjay ^a   Woolfson, Peter ^a   Waldek, Stephen ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

Enzyme replacement therapy; Fabry disease; Left ventricular hypertrophy

Indexed keywords

AGALSIDASE BETA;

ADULT; AGE; ARTICLE; ASCENDING AORTA; CHILL; CLINICAL FEATURE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; ELECTROCARDIOGRAM; ENZYME REPLACEMENT; FABRY DISEASE; FABRY OUTCOME SURVEY MAINZ SEVERITY SCORE INDEX; FEMALE; FEVER; GENDER; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; P WAVE; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RETROSPECTIVE STUDY; SIDE EFFECT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

ADULT; ALPHA-GALACTOSIDASE; AORTA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84866151406     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.05.011     Document Type: Article

References (37)

1. Desnick R.J., Brady R., Barranger J., Collins A.J., Germain D.P., Goldman M., Grabowski G., Packman S., Wilcox W.R. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann. Intern. Med. 2003, 138:338-346.
2. Wilcox W.R., Oliveira J.P., Hopkin R.J., Ortiz A., Banikazemi M., Feldt-Rasmussen U., Sims K., Waldek S., Pastores G.M., Lee P., Eng C.M., Marodi L., Stanford K.E., Breunig F., Wanner C., Warnock D.G., Lemay R.M., Germain D.P., Fabry Registry Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol. Genet. Metab. 2008, 93:112-128.
3. Mehta A., Ricci R., Widmer U., Dehout F., Garcia de Lorenzo A., Kampmann C., Linhart A., Sunder-Plassmann G., Ries M., Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur. J. Clin. Invest. 2004, 34:236-242.
4. Linhart A., Kampmann C., Zamorano J.L., Sunder-Plassmann G., Beck M., Mehta A., Elliott P.M., European FOS Investigators Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur. Heart J. 2007, 28:1228-1235.
5. Barbey F., Qanadli S.D., Juli C., Brakch N., Palacek T., Rizzo E., Jeanrenaud X., Eckhardt B., Linhart A. Aortic remodelling in Fabry disease. Eur. Heart J. 2010, 31:347-353.
6. Namdar M., Steffel J., Vidovic M., Brunckhorst C.B., Holzmeister J., Lüscher T.F., Jenni R., Duru F. Electrocardiographic changes in early recognition of Fabry disease. Heart 2011, 97:485-490.
7. Linhart A., Palecek T., Bultas J., Ferguson J.J., Hrudová J., Karetová D., Zeman J., Ledvinová J., Poupetová H., Elleder M., Aschermann M. New insights in cardiac structural changes in patients with Fabry's disease. Am. Heart J. 2000, 139:1101-1108.
8. Namdar M., Kampmann C., Steffel J., Walder D., Holzmeister J., Lüscher T.F., Jenni R., Duru F. PQ interval in patients with Fabry disease. Am. J. Cardiol. 2010, 105:753-756.
9. Pochis W.T., Litzow J.T., King B.G., Kenny D. Electrophysiologic findings in Fabry's disease with a short PR interval. Am. J. Cardiol. 1994, 74:203-204.
10. Weidemann F., Breunig F., Beer M., Sandstede J., Störk S., Voelker W., Ertl G., Knoll A., Wanner C., Strotmann J.M. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur. Heart J. 2005, 26:1221-1227.
11. Thurberg B.L., Rennke H., Colvin R.B., Dikman S., Gordon R.E., Collins A.B., Desnick R.J., O'Callaghan M. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002, 62:1933-1946.
12. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human-galactosidase A replacement therapy in Fabry's disease. N. Eng. J. Med. 2001, 345:9-16. International Collaborative Fabry Disease Study Group.
13. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., Brady R.O. Enzyme replacement therapy in Fabry disease. JAMA 2001, 285:2743-2749.
14. Weidemann F., Breunig F., Beer M., Sandstede J., Turschner O., Voelker W., Ertl G., Knoll A., Wanner C., Strotmann J.M. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003, 108:1299-1301.
15. Spinelli L., Pisani A., Sabbatini M., Petretta M., Andreucci M.V., Procaccini D., Lo Surdo N., Federico S., Cianciaruso B. Enzyme replacement therapy with agalsidase improves cardiac involvement in Fabry's disease. Clin. Genet. 2004, 66:158-165.
16. Imbriaco M., Pisani A., Spinelli L., Cuocolo A., Messalli G., Capuano E., Salvatore M. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 2009, 95:1103-1107.
17. Mehta A., Beck M., Elliott P., Giugliani R., Linhart A., Sunder-Plassmann G., Schiffmann R., Barbey F., Ries M., Clarke J.T., Fabry Outcome Survey investigators Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009, 374:1986-1996.
18. Kovacevic-Preradovic T., Zuber M., Attenhofer Jost C.H., Widmer U., Seifert B., Schulthess G., Fischer A., Jenni R. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. Eur. J. Echocardiogr. 2008, 9:729-735.
19. Koskenvuo J.W., Hartiala J.J., Nuutila P., Kalliokoski R., Viikari J.S., Engblom E., Penttinen M., Knuuti J., Mononen I., Kantola I.M. Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J. Inherit. Metab. Dis. 2008, 31:432-441.
20. Banikazemi M., Bultas J., Waldek S., Wilcox W.R., Whitley C.B., McDonald M., Finkel R., Packman S., Bichet D.G., Warnock D.G., Desnick R.J. Agalsidase-beta therapy for advanced Fabry disease. Ann. Intern. Med. 2007, 146:77-86. Fabry Disease Clinical Trial Study Group.
21. Romhilt D.W., Estes E.H. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am. Heart J. 1968, 75:752-758.
22. Perkiömäki J.S., Koistinen M.J., Yli-Mayry S., Huikuri H.V. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J. Am. Coll. Cardiol. 1995, 26:174-179.
23. Garson A. How to measure the QT interval-what is normal?. Am. J. Cardiol. 1993, 72:14B-16B.
24. Teichholz L.E., Kreulen T., Herman M.V., Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of asynergy. Am. J. Cardiol. 1976, 37:7-11.
25. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 1986, 57:450-458.
26. Levy D., Savage D.D., Garrison R.J., Anderson K.M., Kannel W.B., Castelli W.P. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am. J. Cardiol. 1987, 59:956-960.
27. Sahn D.J., DeMaria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978, 58:1072-1083.
28. Whybra C., Kampmann C., Krummenauer F., Ries M., Mengel E., Miebach E., Baehner F., Kim K., Bajbouj M., Schwarting A., Gal A., Beck M. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin. Genet. 2004, 65:299-307.
29. Whybra C., Baehner F., Baron K. Measurement of disease severity and progression in Fabry disease. Fabry Disease: Perspectives from 5Years of FOS 2006, 315-322. Oxford PharmaGenesis, Oxford. A. Mehta, M. Beck, G. Sunder-Plassmann (Eds.).
30. Schaefer E., Mehta A., Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry outcome survey. Acta Paediatr. Suppl. 2005, 94:87-92.
31. Weidemann F., Niemann M., Breunig F., Herrmann S., Beer M., Störk S., Voelker W., Ertl G., Wanner C., Strotmann J. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009, 119:524-529.
32. Beck M., Ricci R., Widmer U., Dehout F., de Lorenzo A.G., Kampmann C., Linhart A., Sunder-Plassmann G., Houge G., Ramaswami U., Gal A., Mehta A. Fabry disease: overall effects of agalsidase alfa treatment. Eur. J. Clin. Invest. 2004, 34:838-844.
33. Breunig F., Weidemann F., Strotmann J., Knoll A., Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006, 69:1216-1221.
34. Barbey F., Brakch N., Linhart A., Rosenblatt-Velin N., Jeanrenaud X., Qanadli S., Steinmann B., Burnier M., Palecek T., Bultas J., Hayoz D. Cardiac and vascular hypertrophy in Fabry disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26:839-844.
35. Shah J.S., Hughes D.A., Sachdev B., Tome M., Ward D., Lee P., Mehta A.B., Elliott P.M. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am. J. Cardiol. 2005, 96:842-846.
36. Wolf C.M., Arad M., Ahmad F., Sanbe A., Bernstein S.A., Toka O., Konno T., Morley G., Robbins J., Seidman J.G., Seidman C.E., Berul C.I. Reversibility of PRKAG2 glycogen-storage cardiomyopathy and electrophysiological manifestations. Circulation 2008, 117:144-154.
37. Reichek N., Devereux R.B. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981, 63:1391-1398.